PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 77.77% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 80.22%, a 36.87% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 127.07%, a 63.50% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 77.72%.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 79.90%, a 2.96% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|
| 2026-06-30 | 77.77% 10-Q · filed 2026-08-14 | ||
| 2025-12-31 | 80.22% 10-K · filed 2026-03-06 | ||
| 2025-09-30 | 80.22% 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 80.22% 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | 127.07% 10-K · filed 2026-03-06 | ||
| 2024-09-30 | 127.07% 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | 86.76% 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | 77.72% 10-K · filed 2026-03-06 | ||
| 2021-12-31 | 79.90% 10-K · filed 2022-03-01 | ||
| 2021-09-30 | 79.90% 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 79.90% 10-Q · filed 2021-08-13 | ||
| 2020-12-31 | 77.60% 10-K · filed 2022-03-01 | ||
| 2020-09-30 | 74.30% 10-Q · filed 2020-11-13 | ||
| 2019-12-31 | 72.69% 10-K · filed 2022-03-01 | ||
| 2018-12-31 | 81.20% 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |